ANI Pharmaceuticals, Inc.
Financials
Valuation Metrics
ANI Pharmaceuticals, Inc.'s Market Cap is $1.73B. At end of 2025 it was $1.58B. Ranked #2137 of 3,121 in US market (top 68%), #837 of 1,463 on NASDAQ (top 57%), #152 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.73B | US#2,137/3,121 Sec#152/266 |
| Revenue | $978M | US#1,900/3,121 Sec#53/266 |
| Net Income | $106M | US#1,599/3,121 Sec#51/266 |
| Total Assets | $1.49B | US#2,266/3,121 Sec#69/266 |
| Net Assets | $597M | US#2,112/3,121 Sec#97/266 |
| Employees | 970 | US#2,001/3,121 Sec#55/266 |
| Value | ||
| P/E | 16.36x | US#853/3,121 Sec#26/266 |
| P/B | 2.90x | US#1,701/3,121 Sec#83/266 |
| P/S | 1.77x | US#1,166/3,121 Sec#21/266 |
| EV/EBITDA | 6.65x | US#329/3,121 Sec#9/266 |
| FCF Yield | 9.21% | US#675/3,121 Sec#21/266 |
| Profitability | ||
| ROE | 17.72% | US#714/3,121 Sec#38/266 |
| ROA | 7.08% | US#777/3,121 Sec#44/266 |
| Op. Margin | 15.35% | US#1,192/3,121 Sec#50/266 |
| Revenue Growth | 30.90% | US#416/3,121 Sec#62/266 |
| Financial Health | ||
| Debt Ratio | 150.18% | US#1,501/3,121 Sec#190/266 |
| Total Debt | $330M | US#2,071/3,121 Sec#76/266 |
| FCF | $159M | US#1,515/3,121 Sec#53/266 |
| Cash | $360M | US#1,291/3,121 Sec#71/266 |
| Current Ratio | 2.91x | US#830/3,121 Sec#197/266 |
| Net Debt/EBITDA | -0.12x | US#526/3,121 Sec#29/266 |
| Performance | ||
| 1Y Return | -21.89% | US#2,421/3,121 Sec#212/266 |
| 1M Return | -2.41% | US#1,205/3,121 Sec#111/266 |
| From 52W High | -21.92% | US#1,697/3,121 Sec#129/266 |
| 1Y MDD | -26.83% | US#1,234/3,121 Sec#71/266 |
| Trading | ||
| Volume | 939,446 shares | US#1,978/3,121 Sec#207/266 |
| Trading Value | $71M | US#1,431/3,121 Sec#112/266 |
| Per Share | ||
| EPS | $4.65 | US#740/3,121 Sec#20/266 |
| BPS | $26.27 | US#1,004/3,121 Sec#21/266 |
Company Info
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.